Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, efficacy, safety, and immunogenicity of SB5 versus Humira in moderate to severe chronic plaque psoriasis (Phase IV)
2022-000695-19Phase 4Completed
- Sponsor
- Samsung Bioepis
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of adalimumab in plaque psoriasis (2 arms), sponsored by Samsung Bioepis. Primary endpoint: AUCtau. Started May 2022; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-000695-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000695-19.